key: cord-0863102-tq642tbj
authors: Oo, Charles; Ameer, Barbara
title: Revamping the Ever-changing Landscape of Drug Development Processes in the Midst of COVID-19 Pandemic
date: 2021-04-29
journal: Drug Discov Today
DOI: 10.1016/j.drudis.2021.04.024
sha: 1ba565282e904466d1eb20668b3149c79668ba6b
doc_id: 863102
cord_uid: tq642tbj

Oncology is the frontline of drug development. The current pharmaceutical pipeline is disproportional focused on oncology, where about 1/3 of all phases of development is in this therapeutic area. The emphasis brings about substantial breakthrough and has made positive impact on the quality of life. However, oncology remains a threat to human existence, and more will be needed. To facilitate this process, a comprehensive list of novel/first molecularly targeted oncology drug approvals by the FDA from 2017 to 2020 is complied. Here, we focus on molecularly targeted oncology drugs and not cytotoxic ones, although the latter remain important. To achieve this purpose, besides their sponsors, years of approval, drug classes, and cancer indications, clinical significance is included. The results show that approved molecularly targeted drugs span across diverse classes, including small molecule receptor inhibitors, and biologics such as monoclonal antibodies, antibody-drug conjugates, check-point inhibitors (i.e., PD1, PDL1, CTLA4) and CAR-T cell therapies. Although complete cure of cancer remains limited, we have made substantial inroads and more is yet to come. Moreover, many of these new knowledge can be extrapolated to other therapeutic areas, especially to those of currently unmet medical needs such as in neurology.

span across diverse classes, including small molecule receptor inhibitors, and biologics such as monoclonal antibodies, antibody-drug conjugates, check-point inhibitors (i.e., PD1, PDL1, CTLA4) and CAR-T cell therapies. Although complete cure of cancer remains limited, we have made substantial inroads and more is yet to come. Moreover, many of these new knowledge can be extrapolated to other therapeutic areas, especially to those of currently unmet medical needs such as in neurology.

Medicine and Dentistry

More specific subject area Cancer drug approval

Name and reference of original method Not applicable

https://www.fda.gov/drugs/new-drugs-fda-cders-newmolecular-entities-and-new-therapeutic-biologicalproducts/novel-drug-approvals-2020

The database is compiled from public information via internet search and the FDA website, https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-andnew-therapeutic-biological-products/novel-drug-approvals-2020.

Compiled list of the US-FDA Novel First Approval of Molecular-Targeted Anti-cancer drugs (2007-2010) is provided separately as an excel file.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. One consolation is that the pandemic is revealing substantial shortcomings in drug development processes, and has accelerated many innovations to meet this health crisis. Many changes have been advocated, some of which are starting to take shape [1] . What is certain is that after this watershed period, the practice of medicine and social behavior will never be the same again.

Here we highlight some actionable proposals within the scope of scientific communities, with examples from oncology, which may further galvanize medical product development in all therapeutic areas.

Drug development success hinges on early partnership among sponsors, clinicians/scientists and regulatory agencies. This type of collaboration was evidenced by the US-FDA, UK-MHRA and EMA initiatives in response to COVID-19. It builds on some of the innovative processes utilized during novel drug approvals by the US-FDA, and among them are the molecularlytargeted therapies in oncology, which are at the forefront of breakthrough in pharmacotherapy [2] . They include small molecules for biomarker-defined enzyme inhibition and biologics such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), check-point inhibitors (i.e., PD1, PDL1, CTLA4) and CAR-T cell therapies [3] .

Nearly all of the recent oncology approvals were awarded the US Orphan Drug Designation and sharing, trust and transparency, and equity in access, among others.

For emergency use and highly unmet medical needs, the traditional step-wise development policies will need to be accelerated. Under such circumstances, the flexible use of fit-forpurpose, risk-based efficacy, safety and chemistry and manufacturing controls (CMC) would be expedient [4] . Medical scenarios warranting regulatory transformations could include not only a pandemic like COVID-19, but also a global antimicrobial resistance crisis and even persistent serious diseases. We cannot afford delay in finding effective interventions for these health dilemmas without further increase in human suffering and death tolls.

Underpinning team success is the ability to marshal the talents of capable clinicians/scientists.

Through them, remarkable progress has been made in our understanding of tumor cell resistance to treatment, ongoing rapid mutations, and the importance of the innate immune response. Breakthrough areas include the early diagnosis and detection using circulating tumor DNA (liquid biopsy), and clinical data assembly through the use of real-world evidence. New knowledgebase acquired specific to the COVID-19 pandemic include use of novel messenger RNA (mRNA) technology in producing vaccines, better understanding of genomic variants and sensitivity of existing diagnostic detection [5] , and in long-term symptomatic patients of postacute COVID-19 syndrome colloquially termed 'long-haulers'.

Addressing unmet medical need is a goal of drug development. In 2009, the FDA finalized a guidance on patient-reported outcomes (PROs) for developers seeking to incorporate PROs such as using symptomatic scores, functional status and health-related quality-of-life assessments. While meaningful to patients and healthcare providers, PROs may rarely achieve US labeling claim status that impact how medications are used; A prominent exception in hematology/oncology includes the PRO-related efficacy claim for ruxolitinib in myelofibrosis [6[. However, patient centricity will grow in prominence, with the recent FDA-initiated Patientfocused Drug Development, wearable devices, remote/virtual trials, and individualized treatments based on genomics. Such approaches accommodate diverse individual characteristics and needs, which tend to be more quantitative and objective, and no longer one-size fits all.

Following a standard approach of drug development through a series of trials, each investigating one or two interventions, is unsustainable. To remedy this situation, novel trial designs were piloted initially in oncology [7] . In 2018, FDA initiated the Complex Innovative

Trial Designs (CID) Pilot Program, followed by a draft guidance to incorporate complex adaptive, Bayesian, and other novel designs. With the urgency imposed by COVID-19, a CID approach may be an appropriate avenue to evaluate new and repurposed medicines [8] .

To elucidate further, master protocols that require a highly coordinated set-up and trial conduct in multiple diseases are more in focus now [9] . With existing master protocols, no reinventing the wheel is necessary. The beauty of master protocols are that they may run trials for years, save substantial resources, and speed up drug development. However, prospective planning is needed to avoid having operational complexity that will offset saving of resources.

One possible way to reduce operational complexity is through the use of more investigator-led trials where trial operators are familiar with existing processes.

Specifically, COVID-19 has made rapid learning essential, where investigators employ adaptive design in platform trials (with appendices). Multiple therapeutic agents can be introduced or withdrawn based on frequent interim looks at the data, applying real-time analysis and prespecified stopping rules [9] . In this way, modern drug discovery pipelines might be accelerated to clinical evaluation at a faster pace. Recent success in the ACTIV Trial, representing international antithrombotic master trial platforms where one of which is for COVID-19 [10] , demonstrates that CID approach is applicable to global drug development. 

Success in building high-performing teams, as in team sports, involves upholding team morale, building trust and fostering transparency and collaboration among stakeholders, including clinicians. Although saving commute time, the absence of face-to-face communication under COVID-19 calls for greater teamwork. With recent advances in technology and coupled with willingness to adapt, it is conceivable that this critical hindrance can be overcome.

By focusing on patient centricity, with efficient drug development as an end-goal in mind, and by upholding team morale while practicing good science and team management, we are poised to navigate the challenges of revamping traditional drug development processes. Out of these efforts to leverage innovative learnings and momentum catalyzed by this crisis, patients with current unmet needs will greatly benefit.

COVID-19 must catalyse changes to clinical development

A time of optimism: Targeted immunotherapeutics as the long-awaited armamentaria against the scourge of human diseases

COVID-19: A catalyst to accelerate global regulatory transformation

Summary of the available molecular methods for detection of SARS-CoV-2 during the ongoing pandemic

Patient-reported outcome labeling for malignant hematology drugs approved in the United States

Novel trial design: A report from the 19th Frontiers Symposium of the American College of Clinical Pharmacology

Repurposing anticancer drugs for the management of COVID-19

Master protocols in clinical trials: a universal Swiss Army knife?

Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients